Key result
Sacubitril/valsartan achieved a higher rate of target blood pressure (61.41% vs 34.8%; p<0.01) and a greater reduction in systolic blood pressure (14.68 vs 6.17 mmHg) compared to valsartan alone.
Why the study?
To evaluate the effectiveness of sacubitril/valsartan versus valsartan in lowering blood pressure in patients with arterial hypertension grade 1-2.
Does sacubitril/valsartan reduce blood pressure more effectively than valsartan in patients with 1-2 degree arterial hypertension?
Cohort (n=105)
Does sacubitril/valsartan reduce blood pressure more effectively than valsartan in patients with 1-2 degree arterial hypertension?
Absolute Event Rate: 61.41% vs 34.8%
p-value: p=<0.01
Sacubitril/valsartan provides superior blood pressure reduction compared to valsartan alone in patients with grade 1-2 hypertension.
Sacubitril/valsartan linked to greater BP reduction than valsartan in small cohort; leaves open role in hypertension pending randomized confirmation.
Objective. To identify the effectiveness of sacubitril/valsartan versus valsartan in reducing blood pressure (BP) in patients with arterial hypertension (HTN) 1–2 degree. Design and methods. The study included 105 patients, among them 90 were included in the effectiveness analysis and were observed for 12 months in an outpatient setting. In accordance with the protocol, 90 patients completed the study, 44 of them received sacubitril/ valsartan (97/103 mg), 46 received valsartan (160 mg). The dynamics of clinical BP in mm Hg and rates of achieving target BP levels in treatment groups were assessed. Results. Systolic after 12 months decreased more significantly in sacubitril/valsartan group versus valsartan: by 14,68 ± 9,33 vs 6,17 ± 4,81 mmHg (p = 0,007). The rate of achieving target BP was higher in the sacubitril/valsartan group (61,41 % vs 34,8 %, p < 0,01). Conclusions. Among patients with 1–2 degree HTN, sacubitril/valsartan reduced blood pressure to a greater extent than valsartan alone and was not inferior to the latter in terms of safety criteria.
No takes yet. Share an insight, caveat, or question.
Мельникова et al. (2024) conducted a cohort in arterial hypertension 1-2 degree (n=105). sacubitril/valsartan vs. valsartan (160 mg) was evaluated on achieving target blood pressure (p=<0.01). Sacubitril/valsartan achieved a higher rate of target blood pressure (61.41% vs 34.8%; p<0.01) and a greater reduction in systolic blood pressure (14.68 vs 6.17 mmHg) compared to valsartan alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: